Vertex Pharmaceuticals Stock Forecast: Where Analysts See the Stock Going by 2027

Nikko Henson • 5 minute read

Last updated Oct 25, 2025

Vertex Pharmaceuticals (NASDAQ: VRTX) remains one of the most profitable names in biotech, powered by its leadership in cystic fibrosis treatments and a growing gene-editing pipeline. Shares trade near $421, down from last year’s highs, but the company’s margins and innovation pipeline continue to draw investor confidence.

Recently, Vertex and CRISPR Therapeutics received regulatory approvals in the U.S. and Europe for Casgevy, the first CRISPR-based gene-editing therapy for sickle cell disease and beta thalassemia. The company also reported promising late-stage results for its VX-548 pain treatment, which could become a non-opioid alternative for acute pain management. These milestones highlight Vertex’s ability to expand beyond its cystic fibrosis franchise and strengthen its long-term growth story.

This article explores where Wall Street analysts think Vertex could trade by 2027. We have pulled together consensus targets and valuation models to outline the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.

Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>

Analyst Price Targets Suggest Modest Upside

Vertex trades at about $421/share today. The average analyst price target is around $481/share, implying roughly 14% upside over the next 12 to 18 months. Forecasts vary widely:

High estimate: ~$603/share
Low estimate: ~$330/share
Median target: ~$478/share
Ratings: 17 Buys, 2 Outperforms, 11 Holds, 1 Underperform, 1 Sell

The modest upside suggests analysts see Vertex as fairly valued after several years of strong performance. However, many believe the company’s next growth chapter could come from its recently approved gene-editing therapy, Casgevy, and its late-stage non-opioid pain candidate, VX-548.

For investors, the stock looks like a steady compounder rather than a high-flyer. Upside could expand if Vertex successfully commercializes these new treatments and proves it can grow beyond its cystic fibrosis franchise.

Vertex Pharmaceuticals stock — Vertex Pharmaceuticals Analyst Price Target

Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>

Vertex: Growth Outlook and Valuation

Vertex’s fundamentals remain robust and supported by multiple growth drivers:

Revenue is projected to grow about 9% annually through 2027
Operating margins are expected near 46%
Shares trade around 22x forward earnings
Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 21.9x forward P/E suggests ~$515/share by 2027
That implies about 22% total upside, or roughly 10% annualized returns

For investors, Vertex offers a defensive growth profile with a rare mix of innovation and profitability. Its cash-rich balance sheet and expanding pipeline provide flexibility to reinvest in new areas like pain, diabetes, and gene therapy.

If upcoming trials for VX-548 and its diabetes program deliver as hoped, Vertex could shift from a single-franchise company into a broader biotech leader, making the current valuation look more attractive over time.

See a stock’s true value in under 60 seconds (Free with TIKR) >>>

What’s Driving the Optimism?

Vertex continues to strengthen its leadership in cystic fibrosis, generating steady cash flow from its core treatments like Trikafta. The company recently made headlines after Casgevy, its CRISPR-based gene-editing therapy developed with CRISPR Therapeutics, received approvals in the U.S. and Europe. This marks the first approved treatment of its kind for sickle cell disease and beta thalassemia, expanding Vertex’s reach beyond its traditional markets.

Meanwhile, Vertex’s VX-548 program in pain management shows promise as a potential non-opioid treatment alternative. If approved, it could open an entirely new therapeutic category for the company. For investors, these developments signal that Vertex is evolving into a diversified biotech with both high-margin legacy products and innovative new growth drivers.

Bear Case: Growth Risks and Pipeline Execution

Despite strong fundamentals, Vertex still depends heavily on cystic fibrosis drugs, which account for most of its revenue. As that market matures, maintaining growth will rely on the success of Casgevy and other pipeline candidates. If launches underperform or clinical results disappoint, near-term earnings growth could slow.

Competition is also increasing across gene therapy and pain treatment categories. For investors, the risk is that execution missteps or slower adoption of new therapies could limit returns, especially if market expectations are already priced in.

Outlook for 2027: What Could Vertex Be Worth?

Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests Vertex could trade near $515/share by 2027, representing about 22% total upside or roughly 10% annualized returns from current levels.

That outlook points to solid, steady compounding rather than dramatic re-rating potential. Vertex’s high margins and expanding pipeline should support consistent earnings growth, but the next phase of upside depends on how well the company commercializes Casgevy and VX-548.

For investors, Vertex looks like a reliable long-term compounder with room for moderate appreciation. The key to unlocking stronger gains will be proving that it can sustain double-digit growth beyond its cystic fibrosis foundation.

Find out what your favorite stocks are really worth (Free with TIKR) >>>

AI Compounders With Massive Upside That Wall Street Is Overlooking

Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.

TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.

Inside the report, you’ll find: